Public-registry trials using FYB203 2 mg (0.05 mL of 40 mg/mL) that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Ocular Safety and Usability Study for FYB203 PFS | Formycon AG | Age-Related Macular Degeneration | PHASE4 | 4 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →